STAAR Surgical Company (STAA) has a 30-year history specializing in products for eye surgery with a treatment for cataracts in 1991 and the introduction of its revolutionary "implantable collamer lenses" marketed as Visian ICL in 1996. The product here is an alternative to laser-based procedures which still maintain the largest share in the global refractive surgery market. STAAR highlights some clinical advantages over treatments like "LASIK" and the recent gain in market share worldwide. The company has posted an impressive 22% composite annual growth rate since 2017 with increasing adoption by ophthalmic surgeons and from